CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Crispr Therapeutics ( ($CRSP) ) has released its Q3 earnings. Here is a breakdown of the information Crispr Therapeutics presented to its investors...

CRISPR Therapeutics Reports Q3 2025 Financial Results

In a report released today, from Oppenheimer maintained a Buy rating on Crispr Therapeutics AG, with a price target of $95.00. In addition to Oppen...

Oppenheimer Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Perspective Therapeutics (CATX – Research Report), C...

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Crispr Therapeutics AG (CRSP) and Upstream Bio, Inc. (UPB)

Barclays analyst Gena Wang maintained a Hold rating on Crispr Therapeutics AG today and set a price target of $56.00. According to TipRanks, Wang i...

Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)

Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all earned Strong Buy ratings from Top Wal...

3 Best Stocks to Buy Now, 11/10/2025, According to Top Analysts

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) reported several trades for Tuesday, November 4, 2025, highlighting new buys in biotech stock...

CRSP, BEAM, ROKU, SOFI: Cathie Wood Pours $17 Million into Biotech Stocks, Trims Tech Favorites

Crispr Therapeutics AG ( ($CRSP) ) has fallen by -8.60%. Read on to learn why. Crispr Therapeutics AG has experienced a notable decline in its stoc...

Crispr Therapeutics AG Faces Stock Price Slump

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Crispr Therapeutics AG, with a price target of $80.00. ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRSP	$54.00	+2.79%	2.96M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRSP	$54.00	+2.8%	2.96M
3
4
5
6

CRSP

CRSP

Get CRISPR Therapeutics AG Data in Excel

Get CRISPR Therapeutics AG Data in Excel